In Boston on December 22, 2025, Ginkgo Bioworks revealed a collaboration with Carnegie-Mellon University, receiving an award from the Advanced Research Projects Agency for Health (ARPA-H) for their POSEIDON program. The partnership with CMU focuses on the Platform Optimizing SynBio for Early Intervention initiative. Ginkgo Bioworks is listed on NYSE as DNA.